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As a master transcription factor in cellular responses
to external stress, tumor suppressor p53 is tightly
regulated. Excessive p53 activity during myocardial
ischemia causes irreversible cellular injury and cardi-
omyocyte death. p53 activation is dependent on
lysine acetylation by the lysine acetyltransferase
and transcriptional coactivator CREB-binding
protein (CBP) and on acetylation-directed CBP
recruitment for p53 target gene expression. Here,
we report a small molecule ischemin, developed
with a structure-guided approach to inhibit the
acetyl-lysine binding activity of the bromodomain of
CBP.We show that ischemin alters post-translational
modifications on p53 and histones, inhibits p53 inter-
action with CBP and transcriptional activity in cells,
and prevents apoptosis in ischemic cardiomyocytes.
Our study suggests small molecule modulation of
acetylation-mediated interactions in gene transcrip-
tion as a new approach to therapeutic interventions
of human disorders such as myocardial ischemia.
INTRODUCTION
Cardiovascular diseases continue to be an epidemic in the
United States and the western world. Half of all hospital admis-
sions are related to cardiovascular disorders; 80% of those
who have fatal consequences are 65 years or older (Gillum
et al., 1998; Wei, 1992). The salient feature of cardiac ischemia,
which is mainly due to coronary syndromes, includes lack of
oxygen and nutrition, which generates stress signals to activate
pathways leading to cardiacmyocyte death. It has been reported
that ischemia-induced myocyte DNA damage results in
enhanced transcriptional activity of the tumor suppressor p53
as well as p53-dependent cardiac myocyte apoptosis; the latter
is a key feature in the progression of ischemic heart disease
(Gudkov and Komarova, 2005; Komarova and Gudkov, 1998).Chemistry & Biology 18,Myocardial ischemia can also induce inflammatory responses
and cardiomyocyte necrosis, depending on the intensity and
duration of ischemia and reperfusion (Fliss and Gattinger,
1996; Kajstura et al., 1996; Lefer and Granger, 2000). Thus, it
appears that attenuation of myocyte apoptosis could potentially
prevent myocyte loss, improve myocardial dysfunction, and
decrease mortality rate that is associated with myocardial
ischemia and reperfusion (Eefting et al., 2004). Previous studies
have shown that exposure of myocytes to hypoxia results in
increased p53 trans-activating activity and protein accumulation
along with the expression of p21/WAF-1/CIP-1, a well-charac-
terized target of p53 transactivation (Long et al., 1997). Although
p53 activation has been recognized for therapeutic potential in
cancer treatments, its hyperactivation could also be detrimental
in both normal and ischemic conditions (Komarova and Gudkov,
1998, 2000). Therefore, in a different biological context, modula-
tion of p53 function as a transcriptional regulator, either activa-
tion or inhibition, could present valid therapeutic opportunities.
Transcriptional coactivators CREB-binding protein (CBP) and
p300 (also known as KAT3B and KAT3A, respectively) (Giordano
and Avantaggiati, 1999; Imhof et al., 1997; Ogryzko et al., 1996;
Sterner and Berger, 2000) play a central role in regulating p53
stability and its function as a transcription factor in response to
genotoxic stress (Ferreon et al., 2009; Ott et al., 1999). The
main functions of CBP/p300 in gene transcription are dependent
on activities of both the lysine acetyltransferase (KAT) and the
acetyl-lysine binding bromodomain (BRD). Like histones, lysine
acetylation of transcription factors facilitates the recruitment of
BRD-containing cofactors required for chromatin structural
change and transcriptional initiation and elongation (Dhalluin
et al., 1999; Mujtaba et al., 2007; Sanchez and Zhou, 2009).
The biochemical contribution of acetylation to p53 transcription
functions has been attributed to nuclear translocation, alteration
of DNAbinding ability and enhancement of transcriptional poten-
tial (Prives andManley, 2001). Previous studies from us and other
laboratories have supported the role of p53 acetylation in
promoting molecular interactions with transcriptional coregula-
tors leading to target gene activation that ultimately determines
cellular responses to stress in the forms of senescence, cell
growth arrest, or apoptosis (Barlev et al., 2001; Mujtaba et al.,
2004; Sakaguchi et al., 1998; Zhao et al., 2006). Specifically,531–541, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 531
Figure 1. Target Structure-Guided Design of Chemical Probes for the CBP Bromodomain
(A) Superimposition of 2D 1H-15N-HSQC spectra of the 15N-labeled CBP BRD highlighting changes of protein NMR resonances on binding to a small molecule,
ischemin (black, free protein; red, in the presence of ischemin).
(B and C) Ribbon diagram of the lowest energy NMR structures of the CBP BRD bound to ischemin (left) versus to histone H4K20ac peptide (right), respectively.
Side chains of the key protein residues at the ligand-binding site are shown and color-coded by atom type. See also Figure S1.
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A CBP Inhibitor Blocks Apoptosis in Cardiomyocyteswedemonstrated that CBP acetylates p53C-terminal lysine resi-
dues on DNA damage, and subsequently the BRD of CBP binds
to p53 at acetylated lysine 382 (p53K382ac), which is essential
for p53-induced transcriptional activation of target genes such
as cyclin-dependent kinase inhibitor 1A (CDKN1A/p21) (Mujtaba
et al., 2004, 2006).
Activation of p53 in cancer is not restricted to the killing of
tumor cells (Rogel et al., 1985). p53-dependent apoptosis also
occurs in sensitive tissues shortly after gamma irradiation
(Komarova et al., 1997a), and p53-deficient mice survive higher
doses of gamma irradiation than do wild-type animals (Westphal
et al., 1997, 1998). These studies highlight the toxic nature of p53
after chemo- and radiation-therapies on normal tissues that
ameliorate the disease condition and extend the recovery in
cancer patients. Therefore, suppression of p53 functions has
been suggested as a therapeutic strategy to prevent damage
of normal tissues (Komarova and Gudkov, 2001). Consequently,
Pifithrin was identified from cell based chemical library
screening, which is probably the first p53 inhibitor reported
(Komarov et al., 1999). In addition to inhibiting p53-dependent
apoptosis, Pifithrin has been shown to reduce the activation of
p53-regulated target genes, including cyclin G, p21/WAF-1/
CIP-1, and MDM2 (Komarov et al., 1999). Anti-apoptotic proper-
ties of Pifithrin has also been demonstrated in cellular andmouse
models of genotoxic stress (Komarov et al., 1999; Liu et al.,
2004), dopamine-induced apoptosis in neurons (Culmsee
et al., 2001, 2003), cisplatin-induced apoptosis in cochlear and
vestibular hair cells (Zhang et al., 2003), as well as endotoxin-
induced apoptosis in liver tissue (Schafer et al., 2003). Despite
these studies, Pifthrin’s mechanism of action, however, is not
well understood (Murphy et al., 2004).
Because activated p53 is associated with CBP in an acetyla-
tion-sensitive manner, we postulated that small molecules
that inhibit the acetyl-lysine binding activity of the BRD of CBP
would inhibit the ability of p53 to direct its target gene activation.
Toward this goal, in this study we have developed small mole-532 Chemistry & Biology 18, 531–541, April 22, 2011 ª2011 Elseviercules that target the CBPBRD, and characterized their biochem-
ical and functional effects of modulating gene transcription in
osteocarcinoma cells and primary cardiomyocytes where DNA
damage represents intracellular signaling during ischemia.
RESULTS
Target Structure-Guided Lead Discovery
We conducted nuclear magnetic resonance (NMR)-based
screening of 3000 diversity chemical compounds selected
from our in-house collection of 115,000 compounds to identify
small molecules for the bromodomain of CBP. Ligand binding
to the protein was detected by monitoring changes of backbone
amide resonances of 15N-labeled CBP BRD in 2D 1H-15N-HSQC
NMR spectra on addition of the chemicals as mixtures of 30.
Subsequently, the positivemixtures with estimated affinity better
than Kd of about 300 mMwere deconvoluted to identify individual
small molecules that bind CBP BRD at the acetyl-lysine binding
site (Figure 1A). This process was guided by our NMR resonance
assignment of the protein. This target structure-based screening
yielded 10 promising hits for the CBP BRD, several of which
share the azobenzene scaffold, as exemplified by 4-hydroxyphe-
nylazo-benzenesulfonic acid MS456 (Table 1). We solved the 3D
structure of MS456 bound to the CBP BRD with NMR spectros-
copy, which reveals that this compound binds at the entrance of
the acetyl-lysine binding pocket in the BRD, thereby blocking the
protein from interacting with lysine-acetylated binding partners
(see Figure S1A available online; Table 2).
Synthesis and Structure-Activity Relationship Analysis
of Chemical Analogs
To improve lead compound binding affinity and selectivity for
the CBP BRD, we synthesized a series of azobenzene analogs
by introducing various chemical functional groups on the
aromatic rings, as well as by changing the sulfonate group
from para- to meta- position with respect to the azo linkage onLtd All rights reserved
Table 1. Structure-Activity Relationships of Azobenzene Compounds in p53 Inhibition
Compound R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 Inhibition (%)a Kd (mM)
b
MS456 OH H H H H H H SO3H H H 4.6
MS450 OH CH3 H H H H H SO3H H H 85.6 76
MS113 OH CH3CH2 H H H H H SO3H H H 25.7
MS451 OH CH3 H H CH3 H H SO3H H H 87.4 44
MS110 OH CH2CHCH2 H H CH3 H H SO3H H H 86.2 104
MS111 OH (CH3)3C H H CH3 H H SO3H H H 22.8
MS105 OH (CH3)2CH H H (CH3)2CH H H SO3H H H 26.4
MS101 OH CH3 H CH3 H H H SO3H H H 82.9
MS103 OH CH3 H CH3 CH3 H H SO3H H H 38.9
MS100 OH H CH3 CH3 H H H SO3H H H 36.4
Ischemin/MS120 OH H NH2 H CH3 H SO3H CH3 H CH3 104.5 19
MS148 OH H CH3CH2(NH2)CH H CH3 H SO3H CH3 H CH3 12.8
MS155 OH H CO2H H CH3 H SO3H CH3 H CH3 13.1
MS119 OH H CH3 CH3 H H SO3H CH3 H CH3 54.0
MS153 OH H CH3 CH3 H H SO3H OH Cl H 39.0
MS131 OH Cl H H H H SO3H CH3 H CH3 49.7
MS124 OH CH3CH2 H H H H SO3H CH3 H CH3 25.0
MS126 OH CH3CH2CH2 H H H H SO3H CH3 H CH3 93.5 97
MS127 OH CH3CH2CO H H H H SO3H CH3 H CH3 86.8 385
MS109 OH CH3 H H CH3 H SO3H CH3 H CH3 60.1
MS130 OH CH2CHCH2 H H CH3 H SO3H CH3 H CH3 40.4
MS129 OH (CH3)2CH H H CH3 H SO3H CH3 H CH3 44.6
MS128 OH (CH3)2CH H H (CH3)2CH H SO3H CH3 H CH3 47.2
MS154 OH Cl H CH3 H H SO3H CH3 H CH3 6.9
MS135 OH NH2 H CH3 H H SO3H CH3 H CH3 54.8
MS118 OH CH3 H CH3 H H SO3H CH3 H CH3 49.7
MS146 OH CH3 H CH3 CH3 H SO3H CH3 H CH3 30.8
All compounds were used at 50 mMconcentration. Percent inhibition was calculated by [1 (A/B)]3 100, where A is the difference of luciferase activity
measured between cells treated with a compound and doxorubicin and the negative control, and B is the difference of luciferase activity between cells
treated with and without doxorubicin.
aCompounds shown 80% + inhibition of p53 activity are highlighted in blue.
bKd (mM) was determined in a titration of protein tryptophan fluorescence change as a function of ligand concentration.
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sized using a two-step reaction scheme (Scheme S1). Specifi-
cally, the synthesis starts with treatment of a substituted sulfa-
nilic acid with concentrated HCL, and resulting amine is
diazotized by addition of sodium nitrite to produce diazonium
salt. The latter is added to a solution containing a substituted
phenol to yield a corresponding diazobenzene compound.
Toward the objective of developing small molecules that could
be used to study effects of inhibiting the stress-induced p53/
CBP interaction in cells, we systematically evaluated structure-
activity relationship (SAR) of these azobenzene analogs in their
ability to inhibit p53 activation in human osteosarcoma (U2OS)
cells. The p53 activation was induced by DNA damage on treat-
ment of doxorubicin, and effects of compound treatment were
measured by p53-dependent p21 luciferase activity (Table 1;
Figure S2A). All compounds were tested at concentration of
50 mM in U2OS cells.
Of the diazobenzene analogs, 5-(2-amino-4-hydroxy-5-
methyl-phenylazo)-2,4-dimethyl-benzenesulfonic acid, MS120,
exhibited most potent cellular activity in inhibiting p53-depen-Chemistry & Biology 18,dent p21 luciferase activity by almost 100% as compared to
the controls. Using a tryptophan fluorescence binding assay
(Sachchidanand et al., 2006), we determined the binding affinity
of MS120 to the CBP BRD to be Kd = 19 mM (Figure S2B), which
is consistent with its cellular p21 inhibition activity as compared
to those analogs that exhibited >80% inhibition of doxorubicin-
induced p53 activation in the p21 luciferase assay (Table 1).
Given its effective cellular protective activity against myocardial
ischemia (see below), we named this compound MS120 as
ischemin. We further determined IC50 = 5 mM for ischemin in
inhibition of p53-induced p21 activation using the luciferase
activity assay, which is markedly stronger than an analog
MS119 with IC50 = 100 mM (Figure 2A). This difference agrees
with the difference in their inhibition activities observed in the
p21 luciferase activity measurement (Table 1; Figure S2A).
Molecular Basis of Lead Recognition by the CBP BRD
To understand the molecular basis of CBP BRD recognition of
the diazobenzenes, we determined the 3D structure of the ische-
min/CBP BRD complex by using NMR (Figure 1B and Table 2;531–541, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 533
Table 2. NMR Statistics of the Structures of the CBP BRD/Ligand
Complexes
NMR Distance and Dihedral
Constraints
CBP BRD/
MS456
CBP BRD/
Ischemin
Distance constraints
Total NOE 2888 2805
Intraresidue 1155 1131
Interresidue 1714 1674
Sequential (ji – jj = 1) 560 554
Medium range (ji – jj < 4) 654 665
Long range (ji – jj > 5) 500 455
Hydrogen bonds 50 50
Intermolecular constraints 53 25
Total dihedral angle restraints
f 81 81
j 81 81
Structure statistics
Violations (mean ± SD)
Distance constraints (A˚) 0.078 ± 0.0072 0.069 ± 0.0064
Dihedral angle
constraints ()
0.50 ± 0.046 0.49 ± 0.19
Maximum dihedral
angle violation ()
0.58 0.63
Maximum distance
constraint violation (A˚)
0.092 1.03
Deviations from idealized geometry
Bond lengths (A˚) 0.0078 ± 0.00014 0.0076 ± 0.00014
Bond angles () 0.86 ± 0.011 0.84 ± 0.012
Impropers () 0.47 ± 0.0051 0.48 ± 0.0084
Average pairwise rmsda (A˚)
Heavy protein 0.76 ± 0.088 0.71 ± 0.12
Backbone protein 0.34 ± 0.074 0.32 ± 0.093
Ramachandran map analysisa (%)
Most favorable regions 78.6 76.2
Additionally allowed regions 17.1 18.7
Generously allowed regions 2.7 3.6
Disallowed regions 1.6 1.5
BRD, bromodomain; CBP, CREB-binding protein; NMR, nuclear
magnetic resonance; rmsd, root-mean-square deviation; SD, standard
deviation.
a Rmsd calculations were performed for 20 final NMR structures of the
CBP bromodomain consisting of residues 11–120. Pairwise rmsd was
calculated among the 20 refined structures.
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ischemin bound to CBP BRD is similar to that of the initial hit
MS456 (Figure S1). It is worth noting that binding ischemin
caused severe line broadening of several protein residues at
the ligand-binding site, which include Pro1110, Phe1111,
Ile1122, Tyr1125, Ile1128, and Tyr1167. The ligand binding
induced line-broadening resulted in a fewer number of intermo-
lecular NOE-derived distance constraints used for the ischemin-
bound structure determination than that for MS456, i.e.,
25 versus 53, respectively (see Table 2). Nevertheless, the ische-
min/CBP BRD structure is better defined than the latter, consis-534 Chemistry & Biology 18, 531–541, April 22, 2011 ª2011 Elseviertent with its higher affinity (Figure S1). Ischemin binds across the
entrance of the acetyl-lysine binding pocket in an extended
conformation with its phenoxyl group forming a hydrogen bond
(2.8 A˚) to the amide nitrogen of Asn1168 in CBP. The latter is
a highly conserved residue in the BRDs whose amide nitrogen
is hydrogen-bonded to the acetyl oxygen of the acetyl-lysine in
a biological binding partner as seen with acetylated-lysine 20
of histone H4 recognition by the CBP BRD (Figure 1B versus Fig-
ure 1C). The sulfonate group forms electrostatic interactions with
guanidinium group of Arg1173 in the BC loop and possibly also
with side chain amide of Gln1113 in the ZA loop.
Ischemin in the acetyl-lysine binding pocket is sandwiched
through hydrophobic and aromatic interactions between the di-
azobenzene and Leu1109, Pro1110, and Val1174 on one side,
Leu1120 and Ile1122 in the ZA loop on the other. Because all
the diazobenzenes contain a para-phenoxyl group, a hydrogen
bond between the phenoxyl with Asn1168 is likely present in all
the compounds when bound to the CBP BRD. As such, this
structure explains our SAR data (Table 1). For instance, with
a para-sulfonate in the diazonbenzene, ortho- but not meta-
substitution of methyl groups on the phenol ring results in
a marked increase in the lead’s ability to inhibit p53-dependent
p21 luciferase activity, e.g., MS450, MS451, and MS101 versus
MS110. Ortho-substitution of a larger alkyl group such as ethyl
(MS113), isopropyl (MS105), or t-butyl (MS111) showed reduced
activity on p21 inhibition as compare to that of ortho-methyl. The
preferred small hydrophobic group at ortho-position is due to its
possible interaction with a small hydrophobic cavity formed with
Ile1122, Tyr1125, and Tyr1167 that is positioned next to the
conserved Asn1168 in the acetyl-lysine binding pocket (see
below).
When resided at meta-position in diazobenzene, sulfonate
establishes electrostatic interactions with guanidinium side
chain of Arg1173 (Figure 1B); this alters CBP preference for
substitutions on the aromatic ring. For instance, inhibition of
p21 expression seems less sensitive to variations of size and
position of hydrophobic substituent groups on the phenol.
Nevertheless, ortho-propyl (MS126) and ortho-ethyl-keto
(MS127) substituted diazobenzenes exhibit 93.5% and 86.8%
inhibition activity, respectively. This preferred ortho-substituent
likely interacts with side chains of Ile1122, Tyr1125, and
Tyr1167, a small hydrophobic pocket embedded in the
acetyl-lysine binding site (Figure 1B). With a meta-amino
substituent, which electron-donating functionality may aid
formation of a hydrogen bond between the phenoxyl in the
diazobenzene and side chain amide of Asn1168 of the protein,
ischemin nearly completely suppresses the p21 expression.
Although many ischemin binding residues in the acetyl-lysine
binding pocket are conserved among human BRDs (Sanchez
and Zhou, 2009), we observed that ischemin exhibits up to
five-fold selectivity for the CBP BRD over several other human
BRDs including PCAF, BRD41, BAZ1B, and BAZ2B as deter-
mined by an in vitro tryptophan fluorescence binding assay
(Figure S2C). This level of selectivity may attribute to several
ischemin binding residues in CBP such as Pro1110, Gln1113,
and Arg1173 that are not conserved in other human BRDs
(Zeng et al., 2008). Collectively, the new structure provides
the detailed molecular basis of ischemin recognition by the
CBP BRD.Ltd All rights reserved
Figure 2. Functional Characterization of CBP BRD Chemical Modulators in Transcription
(A) Dose-dependent inhibition of p21 luciferase activity in U2OS cells on treatment of ischemin or MS119. The luciferase activity was normalized to Renilla
luciferase as a control. The IC50 was calculated using PRISM software. Error bars represent the data obtained from the experiments repeated three times ormore.
(B) Effects of the CBP BRD ligands on BRDU incorporation in U2OS cells on doxorubicin treatment. The data showing that ischemin or MS119 prevents
a doxorubicin-induced decrease of BRDU incorporation. Error bars represent the data obtained from the experiments repeated three times or more.
See also Figure S2.
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Stress
DNA damage induced by doxorubicin leads to p53 stimulated
cellular responses including cell cycle arrest, damage repair,
and apoptosis (Prives and Hall, 1999; Vogelstein et al., 2000;
Woods and Vousden, 2001). To determine the effect of ischemin
on dividing U2OS cells, we treated U2OS cells with 5-bromo-2-
deoxyuridine (BRDU) and measured the incorporated BRDU
during in DNA synthesis using an ELISA assay. The result
showed that doxorubicin treatment of U2OS cells resulted in
a 45% decrease of BRDU incorporation, indicative of doxoru-
bicin induced cell cycle arrest. However, the presence of ische-
min or MS119 (50 mM) almost completely prevented U2OS cells
from undergoing doxorubicin-induced cell cycle arrest (Fig-
ure 2B). Note that these results also indicate that ischemin is
not toxic to the cells at this concentration.
We then examined biochemical effects of ischemin on p53
stability and function as transcription factor. We incubated
U2OS cells in the presence of doxorubicin with or without ische-
min at concentration of 50 or 100 mM for 24 hr. Subsequently,
cellular proteins were subjected to western blot analysis. As
shown in Figure 3A, the doxorubicin-induced increased levels
of p53 protein, its Ser15-phosphorylated (p53S15p) and
Lys382-acetylated (p53K382ac) forms underwent marked
reduction in the presence of ischemin as assessed by direct
western blots of cell lysate or after immunoprecipitation. Further,
we observed that p53 directed expression of its target genes
p21, PUMA and 14-3-3 s induced by doxorubicin retreatment
was significantly decreased in the presence of ischemin whereas
the level of actin remained the same.
As a transcription factor, p53 ability to activate gene expres-
sion is also dependent on chromatin modifications. Because
CBP acetylates both histones and p53, we evaluated possible
changes of epigenetic marks on p53 and global histones in pres-
ence of ischemin. The western blot analysis of the nuclear
extracts from U2OS cells revealed that p53 inhibition by ische-
min is associated with an increase in histone H3 phosphorylation
at Ser10 and a decrease in H3 acetylation at Lys9 (Figure 3B).
These changes of posttranslational modifications on p53 andChemistry & Biology 18,histone H3 are associated with downregulation of p21, PUMA
and 14-3-3, but not the controls of actin, histone H3, and lamin
B. Noticeably, ischemin treatment did not affect the level or func-
tional phosphorylation state of ATM and CHK1, which are the
upstream signal transducers of p53 (Figure 3B). Collectively,
these results suggest that ischemin inhibits doxorubicin-induced
p53 activation and transcriptional functions by altering post-
translational modification states on p53 and histones.
We further investigated whether ischemin downregulates p53
by blocking p53 binding to CBP. We overexpressed hemagglu-
tinin-tagged CBP (HA-CBP) and Flag-tagged p53 (Flag-p53) in
human embryonic kidney (HEK) 293T cells. Treatment of the
293T cells with ischemin in the presence or absence of doxoru-
bicin did not affect the expression of HA-CBP or Flag-p53, or
acetylation and phosphorylation levels on p53 as assessed by
immunoprecipitation with anti-Flag antibody followed by
western blot analysis using specific antibodies (Figure 3C). The
results reveal that ischemin was clearly capable of inhibiting in
a dose-dependent manner p53 binding to CBP, particularly on
under doxorubicin treatment (Figure 3C, lanes 8 and 9 versus
lane 7). Note that p53 associated with HA-CBP is phosphory-
lated on Ser15, indicating that p53 is transcriptionally active.
These results confirm that ischemin inhibits p53-induced p21
activation on doxorubicin exposure by blocking p53 recruitment
of CBP, which is required for p53 target gene activation (Mujtaba
et al., 2004).
Ischemin Inhibits p53 Cellular Signaling Pathways
We next investigated selectivity of ischemin in transcription inhi-
bition of p53 target genes using a RT-PCR array analysis of RNA
isolated from biological samples of U2OS cells (Figure 4A). The
results show that doxorubicin treatment upregulated p53 target
genes that include CCNB2, CCNH, CDC25C, and CDK4, but did
not affect housekeeping genes GAPDH, b-2 microglobulin (B2M)
and actin (ACTB) (Figure 4B; also see Figure S3). On the other
hand, ischemin can differentially reduce doxorubicin-induced
expression of p53 target genes CCNE2, CCNG2, CDC2,
CDC25A, CDKN1A, CDKN2A (p21), GADD45A, E2F1, E2F3,
PCNA, SESN1, and SESN2 (Figure 4B). These gene products531–541, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 535
Figure 3. Effects of Ischemin on p53 Activation Induced by DNA Damage
(A) Immunoblots showing ischemin effects on levels of endogenous p53, p53 phosphorylation on serine 15, p53 acetylation on lysine 382, as well as p53 target
genes.
(B) Immunoblots showing ischemin effects on levels of correlated H3K9 acetylation and H3S10 phosphorylation, and unaffected upstream kinases CHK1 and
ATM on doxorubicin treatment.
(C) Inhibition of overexpressed HA-tagged CBP and flag-tagged p53 interaction in 293T cells by ischemin in a concentration-dependent manner under doxo-
rubicin-induced DNA damaging condition. An arrow indicates the expressed Flag-tagged p53 in the HEK293T cells.
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p53, of which the best known is CDKN1A (p21) that functions as
an inhibitor for cell cycle progression. Taken together, these
results confirm our hypothesis that small-molecule inhibition of
the acetyl-lysine binding activity of the CBP BRD could downre-
gulate p53 activation and its ability to activate its target genes
under stress conditions.
Ischemin Functions as a Cellular Protective Agent
against Myocardial Ischemic Stress
Wenext investigated whether ischemin could inhibit apoptosis in
cardiomyocytes under DNA damage stress. Primary neonatal rat
cardiomyocytes were isolated and maintained in culture, then,
treated with doxorubicin for 24 hr to induce DNA damage in
the presence or absence of ischemin. The DNA damage induced
by apoptosis was analyzed by the TUNEL (terminal deoxynu-
cleotidyl transferase dUTP nick and end labeling) assay, in which
a terminal deoxynucleotidyl transferase was used to identify
30-OH of DNA generated by DNA fragmentation resulting from
apoptosis, and then labels it with biotinylated dUTP. The latter
was then detected with avidin-conjugated FITC for specific
staining. Using this TUNEL assay we observed that doxorubicin
treatment induces apoptosis in the cardiomyocytes (Figure S4),
and observed that ischemin, which has no toxicity of its own, can536 Chemistry & Biology 18, 531–541, April 22, 2011 ª2011 Elseviereffectively inhibit doxorubicin-induced apoptosis in the cardio-
myocytes (Figure 5A). Further, similar to U2OS cells, we
confirmed that ischemin was able to inhibit doxorubicin induced
p53 activation in the primary neonatal rat cardiomyocytes, but
did not alter H2AX phosphorylation at Ser139 (Figure 5B). The
latter argues that ATM is active in presence of ischemin, which
is consistent with our analysis using western blots (Figure 3B).
We further examined and concluded that ischemin likely blocks
apoptosis in cardiomyocytes by inhibiting caspase 3/7 activity in
a dose-dependent manner (Figure 5C). Finally, we ruled out that
ischemin’s ability to directly inhibit the lysine acetyltransferase
activity of CBP/p300 toward a histone H3 peptide substrate in
a fluorescence-based assay (data not shown). Taken together,
these results strongly demonstrate that ischemin is cell perme-
able and capable of functioning as a cellular protective agent
against myocardial damage by downregulating p53-induced
apoptosis under the stress conditions.
DISCUSSION
Cardiac dysfunction results from the loss of myocyte mass via
necrosis and apoptosis (Joaquin and Gollapudi, 2001; Kajstura
et al., 1996; Vanden Hoek et al., 2003). Necrosis is a passive
process that causes injury to cellular membranes resulting inLtd All rights reserved
Figure 4. Microarray Analysis of Effects of Ischemin on p53 Target Gene Expression, as Assessed by Using Ingenuity System
(A) Heat-map of the microarray data of selected genes in U2OS cells on doxorubicin treatment with and without ischemin. Changes of gene expression are
highlighted in red and green as for up- or downregulation as compared to the control, respectively.
(B) Schematic illustration of selected genes associated with p53 signaling pathways that underwent change of expression levels on doxorubicin treatment with
(left panel) and without (right panel) the presence of ischemin. Gene products are color-coded in red (increase in expression), green (decrease in expression), and
white (no significant change in expression).
Figure S3 depicts a more complete signaling diagram of the genes subject to the microarray analysis. A, activation; E, expression; EC, phosphorylation; I,
inhibition; M, modification; PP, protein-protein interaction; RE, reaction.
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tory responses. In contrast, apoptosis is an active, gene-
directed, and energy-requiring process, in which cells initiate
their own death in response to either internal or external stimuli
(Coopersmith et al., 1999; Freude et al., 2000; Misao et al.,
1996). The p53-dependent apoptosis is a key mechanism by
which the host eliminates unwanted or damaged cells thereby
ensuring the overall genome integrity (Schafer et al., 2003).
Several published studies indicated that apoptosis is the major
form of cell loss and that p53-dependent apoptosis plays a crit-
ical role in myocardial infarction and reperfusion injury and also
in doxorubicin induced cardiomyopathy (Grazette et al., 2004;
Komarov et al., 1999). Pifthrin-a, probably the only known p53
inhibitor, has been shown to inactivate p53 function during
cardiac ischemia (Gudkov and Komarova, 2005; Komarov
et al., 1999; Liu et al., 2004). However, its mechanism of actionChemistry & Biology 18,is not clearly understood. In this study, we have rationally
designed and developed a new p53 inhibitor, ischemin, which
targets p53 interaction with coactivator CBP that is required
for p53 transcriptional activity. We have demonstrated that
ischemin can effectively inhibit transcription functions of p53
on DNA damage and block cardiac myocyte apoptosis during
ischemia conditions.
As a master regulator of transcriptional program p53 controls
genomic stability by inducing growth arrest or apoptosis in
response to either genotoxic stress or activation of oncogenes,
thereby protecting normal cell populations from potential
tumor progenitors (Vousden, 2000). p53 is frequently mutated
in tumors (Soussi and Beroud, 2001). p53-deficient tumors
are usually sensitive to ectopically expressed p53 (May and
May, 1999) and considered to be targets for p53 gene
therapy (Fang and Roth, 2003; Willis and Chen, 2002).531–541, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 537
Figure 5. Ischemin Functions as a Cellular Protective Agent against Myocardial Ischemic Stress
(A) TUNEL assay showing ischemin inhibition of doxorubicin-induced apoptosis in rat neonatal cardiomyocytes.
(B) Evaluation of ischemin effects in U2OS cells and cardiomyocytes. The immunoblots show downregulation of doxorubicin-induced activated p53 in both cell
types in the presence of ischemin, whereas levels of H2XS139p remained the same.
(C) Inhibition of doxorubicin-induced caspase 3/7 activation in cardiomyocytes by ischemin. Error bars represent the data obtained from the experiments
repeated three times or more.
See also Figure S4.
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A CBP Inhibitor Blocks Apoptosis in CardiomyocytesHowever, p53-mediated apoptosis has also been reported to
occur in gastrointestinal tract and hemopoietic cells during
radio and/or chemotherapy, which can result in severe and
well-known side effects of cancer treatment (Chow et al.,
2000; Cui et al., 1995; Komarova et al., 1997a, 1997b; Song
and Lambert, 1999). Therefore, balancing p53 activation in
a temporal manner likely holds therapeutic benefits. The
primary challenge of this strategy is to block activation of
downstream targets of p53 without affecting the upstream
pathway of p53 (such as ATR, ATM and ChK kinases). As
shown in this study, ischemin can selectively downregulate
p53 down-stream target genes without affecting p53 upstream
effector proteins and protect the primary rat cardiomyocyte
cells from ischemic apoptosis through inhibiting caspase 3/7
activity.
As shown in previously reported studies by us and the others
(Barlev et al., 2001; Mujtaba et al., 2004, 2006), bromodomain/
acetyl-lysine mediated protein-protein interactions likely play
an important role in different steps in stress-induced activation
of p53 in gene transcription. These include: (1) coactivator
CBP/p300 or PCAF binding to p53 leading to acetylation of
multiple lysine residues on p53; (2) coactivator recruitment by
acetylated p53 to its target gene loci to increase histone lysine
acetylation; (3) recruitment of chromatin remodeling complexes
to facilitate chromatin opening; and (4) assembly of the active538 Chemistry & Biology 18, 531–541, April 22, 2011 ª2011 Elseviertranscriptional machinery for productive gene transcriptional
activation and elongation. Although the coactivator CBP/p300
has been implicated to participate in all these steps of p53-
induced gene activation, the detailed underlying molecular
mechanism is yet to be fully elucidated. Other bromodomain-
containing proteins could also participate in the process. Given
the modest affinity of ischemin to CBP BRD, we cannot rule
out ischemin binding to possibly other bromodomain proteins
in cells. Nevertheless, additional chemical modifications of the
diazobenzene scaffold could be explored, which can be guided
by our new insights into the molecular basis of ligand recognition
by the target protein. Furthermore, it is conceivable that the
diazo moiety could be replaced by carbon-carbon connectivity,
which could result in an improvement of chemical stability of lead
compounds in cells.
In summary, the new small molecule probes, as described
in this study, lay an important foundation to facilitate future
functional investigation of endogenous p53 under biologically
relevant conditions. Further, we expect that combined use of
additional small molecule probes that are high affinity and selec-
tive for bromodomains fromother chromosomal proteins such as
PCAF and BRD4 will further help us dissect detailed mechanistic
insights into the complex biological functions of p53 in gene tran-
scriptional control in response to cellular stress in human biology
of health and diseases such as myocardial ischemia.Ltd All rights reserved
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Posttranslational modifications of proteins are essential
in cellular control of physiological processes; their dysregu-
lation has been recognized as the cause of human diseases.
Use of small molecules targeting enzymatic activities
responsible for such amino acid modifications is an
accepted approach in drug discovery as exemplified by the
development of kinase inhibitors for cancer treatments
(Chico et al., 2009). We argue, however, that small molecule
targeting of modification-mediated protein-protein interac-
tions offers unique advantages, particularly in regulation of
gene transcription in chromatin. This is because protein
functional domains likely have a fewer number of cellular
binding partners than that of a given chromatin modifying
enzymes. These protein domains have also been shown to
bind to modified amino acids of biological partners with
high specificity but modest affinity (1–100 mM) (Sanchez
and Zhou, 2009; Zeng et al., 2008), which allows necessary
dynamic regulation of cellular biology such as gene
transcription (Huang et al., 2009). As illustrated in this study,
inhibition of acetylation-mediated protein-protein interac-
tions via the bromodomain with selective small molecules
can provide a temporal modulation of gene transcription in
a chromatin context. Therefore, our study highlights an
alternative approach to the future development of new
therapeutic strategies to ameliorate stress-induced human
cardiovascular disorders such as myocardial ischemia.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
All compounds were synthesized using commercially available starting mate-
rials without further purification unless otherwise stated. See Supplemental
Experimental Procedures for details.
Cell Lines, Plasmids, and Reagents
U2OS cells were grown in Eagle’s minimal essential medium (DMEM) (Medi-
atech) supplemented with 10% fetal bovine serum (Invitrogen) and antibiotics
(Invitrogen). For p53activation, doxorubicin (Sigma)wasused. The compounds
were dissolved in DMSO (Sigma). The antibodies used for immunoprecipitation
and western blot are p53 (sc-6243), p21 (sc-397), 14-3-3 (sc-7683), lamin B
(sc-6215) from Santa Cruz Biotech; p53Ser15p (9282), p53K382ac (2525),
ATM (2873), ATMp1981 (4526), CHK (2345), CHKp (2341), and PUMA (4976)
from Cell Signaling Technology; H3 (ab1791), H3KS10p (ab14955), H3K9ac
(ab4441) from ABCAM; and Actin (A4700) from Sigma.
Western Blotting
U2OS cells were harvested cells and lysed in lysis buffer (20 mM Tris (pH 8.0),
150 mM NaCl, 1 mM EGTA, 1% Triton X-100, and 50 mM NaF) containing
protease inhibitor cocktail (Sigma). The cells were sonicated and spun down
at 14,000 rpm for 30 min at 4C. After protein estimation, 30–50 mg of lysates
were subjected to SDS-PAGE, transferred onto nitrocellulose membranes,
blocked with 5% milk/PBS and blotted with a primary antibody. Horse radish
peroxidase-labeled secondary antibodies (goat anti-mouse or anti-rabbit)
were added for 60 min at room temperature, and the blots were washed
with TBS (20 mM Tris, 150 mM NaCl, and 0.05% Tween-20) and subjected
to autoradiography after development of reaction by ECL (GE Health Care).
Luciferase Assay
U2OS Cells were transfected with p21 luciferase (1 mg) and Renilla luciferase
(100 ng) vectors in 6-well plate format using Fugene 6 (Roche). Briefly, total
of 1.1 mg of vector was incubated with 3 ml of Fugene 6 reagent for 30 min.Chemistry & Biology 18,After 3–4 hr of transfection, cell were treated with compounds for overnight,
and then exposed to 300 ng of doxorubicin for next 24 hr. In these experi-
ments, DMSO, transfected cells with empty vector and cell without doxoru-
bicin were used as controls. DMSO concentration is maintained at 0.01%.
Transfected cells with doxorubicin treatment were used as positive control.
The luciferase activity was estimated by following the manufacturer’s instruc-
tion (Promega) in a luminometer. Both active and passive lysis of cells yielded
consistent results. The inhibitory activity (IC50) of a small molecule on p21 lucif-
erase activity was obtained from the average of three biological replicates
using PRISM software.
BRDU Cell Cycle Analysis
BRDU incorporation assay for cell cycle evaluation was performed in 96-well
plates using calorimetric based kit from Calbiochem (catalog #QiA58). One
hundred microliters of 1 3 105/ml cells were plated in DMEM media (Medi-
atech) with 10% fetal bovine serum (FBS). After 12 hr, cells were treated
with compounds ischemin and MS119 (50 mM) with or without doxorubicin
treatment (5 mM). The controls were DMSO and untreated cells. BRDU was
added for 24 hr treatment. After 24 hr, cells were fixed and treated with anti-
BRDU antibody. After washing, the wells were incubated with peroxidase.
After final wash, the color was developed using TMB as substrate and the
reaction was stopped with stop solution and optical density was estimated
at 450 nm.
HA-CBP and Flag-p53 Pull-Down Assay
HA-CBP and Flag-p53 were transfected into human embryonic kidney (HEK)
293T cells with recommended amount of Fugene 6 (Roche). After transfection,
the HA-CBP and Flag-p53 cotransfected cells were treated with ischemin in
the presence or absence of doxorubicin. To test the inhibitory potential of
ischemin against CBP and p53 association, CBPwas first immunoprecipitated
by pulling-down with HA-agarose beads (Sigma) and its association with p53
was then determined with western blot using anti-Flag antibody (Sigma).
Microarray Analysis
Effects of ischemin on transcription inhibition of p53 target genes were as-
sessed using a RT-PCR array study. The array was performed on RNA isolated
from three different biological repeats in U2OS cells using a set of primers
selected for a group of genes that are known to be associated within p53
signaling pathways. The differentially expressed genes in treated related to
untreated groups, i.e., doxorubicin treated versus untreated, or doxorubicin
plus ischemin versus doxorubicin alone, were subjected to pathway analysis
by using the Ingenuity System software (http://www.ingenuity.com/). The
fold changes of these genes were converted to log2Ratio and then imported
into IPA tool along with gene symbols. The enriched pathways in the gene
list were identified by Fisher exact test at p value of 0.05 and visualized in
Canonical pathway explorer.
Cardiac Myocyte Isolation
Neonatal rat ventricular myocytes were isolated by enzymatic dissociation of
cardiac ventricle from 1–2-day-old Sprague-Dawley pups using the Worthing-
ton neonatal cardiomyocyte isolation system (Worthington). Briefly, the pups
were anesthetized and their hearts were excised. The ventricular tissues
were minced in ice cold HBSS and then digested with trypsin overnight at
4C followed by collagenase treatment for 45min at 37C. Cells were collected
by centrifugation at 800 rpm for 5min and subsequently underwent two rounds
of preplating on culture dishes to minimize nonmyocyte contamination. The
enriched cardiomyocyteswere cultured in DMEM/F12 nutrient mixture (Invitro-
gen) with 10%horse serum and 5% fetal calf serum (Invitrogen). After 48 hr, the
medium was changed to DMEM/F12 containing 1% insulin, transferrin, and
selenium media supplement (ITS; Invitrogen) and 0.1% BSA.
Apoptosis Assays in Cardiomyocytes
Caspase 3/7 and TUNEL assays were performed to assess inhibition of
apoptosis by ischemin. Caspase assay and TUNEL assays were performed
using Caspase-Glo 3/7 and DeadEnd kits from Promega. Caspase assay
was performed on live cardiomyocytes in 96-well plates on 3 different days.
Similarly, TUNEL assay was performed in triplicate on 3 different days. For
caspase assay 7500 cardiomyocytes were plated in 96-well plates. After531–541, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 539
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A CBP Inhibitor Blocks Apoptosis in Cardiomyocytestreatment with compounds overnight and then doxorubicin for 24 hr, the inten-
sities of luminescencewere read.Similarly, theTUNELassaywasperformedon
cardiomyocytes attached on coverslips. Briefly, cells were fixedwith 4% para-
formaldehyde in phosphate buffer saline and permeabilized with 0.5% Tween
20 for 10 min. The TUNEL reaction was performed on cells with nucleotide
labeled with FITC by following manufacturer’s instruction.
ACCESSION NUMBERS
Coordinates for the 3D NMR solution structures of CBP bromodomain bound
to ischemin andMS456 are deposited in the Protein Data Bank with accession
numbers of PDB ID 2L84 and 2L85, and RCSB ID RCSB102075 and
RCSB102076.
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